Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | MASP2 | O00187 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20698647 | 0.88 | GLA (0.37) | GRM5MRGPRX4KCNH2TACR1GLA | |
| SCHEMBL17069262 | 0.82 | IDO1 (0.52) | IDO1TACR1 | |
| SCHEMBL25869234 | 0.81 | TACR1 (0.34) | GRM5MRGPRX4KCNH2TACR1GLA | |
| SCHEMBL20698866 | 0.81 | GRM5 (0.41) | GRM5MRGPRX4IDO1ADRA1DNR3C1 | |
| SCHEMBL29193306 | 0.79 | MAPT (0.35) | GRM5MRGPRX4ADRA1DNR3C1NR3C2 | |
| SCHEMBL29193308 | 0.79 | MAPT (0.35) | GRM5MRGPRX4ADRA1DNR3C1NR3C2 | |
| SCHEMBL23373692 | 0.78 | GRM5 (0.39) | GRM5MRGPRX4IDO1ADRA1DNR3C1 | |
| SCHEMBL23159233 | 0.77 | ADRA1D (0.38) | GRM5ADRA1DNR3C1NR3C2KCNH2 | |
| SCHEMBL20980896 | 0.76 | TACR1 (0.44) | MRGPRX4IDO1TACR1 | |
| SCHEMBL25292712 | 0.75 | TSHR (0.33) | GRM5MRGPRX4ADRA1DNR3C1NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708326-B2 | Immunomodulator compounds | CHEMOCENTRYX, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708326-B2 | Immunomodulator compounds | CHEMOCENTRYX, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20210236476-A1 | METHODS OF TREATING CANCER WITH SMALL MOLECULE PD-L1 INHIBITORS | CHEMOCENTRYX, INC. | 2021-08-05 | — | — | US | disclosed |
| US-20210147356-A1 | IMMUNOMODULATOR COMPOUNDS | CHEMOCENTRYX, INC. | 2021-05-20 | — | — | US | disclosed |
| US-10919852-B2 | Immunomodulator compounds | CHEMOCENTRYX, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| US-20190135745-A1 | IMMUNOMODULATOR COMPOUNDS | CHEMOCENTRYX, INC. | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135745-A1 | IMMUNOMODULATOR COMPOUNDS | IL2, FCGRT, IFNG | GRM5 1806/4885MRGPRX4 95/4885IDO1 71/4885 |
| US-11708326-B2 | Immunomodulator compounds | IL2, FCGRT, IFNG | GRM5 1806/4885MRGPRX4 95/4885IDO1 71/4885 |
| US-20210147356-A1 | IMMUNOMODULATOR COMPOUNDS | IL2, FCGRT, IFNG | GRM5 1806/4885MRGPRX4 95/4885IDO1 71/4885 |
| US-20210236476-A1 | METHODS OF TREATING CANCER WITH SMALL MOLECULE PD-L1 INHIBITORS | CD4, CD274, PDCD1 | GRM5 3527/4885MRGPRX4 1078/4885IDO1 18/4885 |
| US-10919852-B2 | Immunomodulator compounds | IL2, FCGRT, IFNG | GRM5 1806/4885MRGPRX4 95/4885IDO1 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.